- Home
- PAMT vs TNXP Comparison
PAMT vs TNXP Comparison
Compare PAMT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAMT
- TNXP
- Stock Information
- Founded
- PAMT 1980
- TNXP 2007
- Country
- PAMT United States
- TNXP United States
- Employees
- PAMT N/A
- TNXP N/A
- Industry
- PAMT Trucking Freight/Courier Services
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- PAMT Industrials
- TNXP Health Care
- Exchange
- PAMT Nasdaq
- TNXP Nasdaq
- Market Cap
- PAMT 272.9M
- TNXP 272.0M
- IPO Year
- PAMT 1985
- TNXP N/A
- Fundamental
- Price
- PAMT $14.22
- TNXP $35.48
- Analyst Decision
- PAMT Hold
- TNXP Strong Buy
- Analyst Count
- PAMT 1
- TNXP 2
- Target Price
- PAMT $12.50
- TNXP $585.00
- AVG Volume (30 Days)
- PAMT 13.1K
- TNXP 729.5K
- Earning Date
- PAMT 07-23-2025
- TNXP 08-15-2025
- Dividend Yield
- PAMT N/A
- TNXP N/A
- EPS Growth
- PAMT N/A
- TNXP N/A
- EPS
- PAMT N/A
- TNXP N/A
- Revenue
- PAMT $687,396,000.00
- TNXP $10,041,000.00
- Revenue This Year
- PAMT N/A
- TNXP $11.66
- Revenue Next Year
- PAMT $9.03
- TNXP $793.18
- P/E Ratio
- PAMT N/A
- TNXP N/A
- Revenue Growth
- PAMT N/A
- TNXP N/A
- 52 Week Low
- PAMT $11.01
- TNXP $6.76
- 52 Week High
- PAMT $23.70
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- PAMT N/A
- TNXP 52.96
- Support Level
- PAMT N/A
- TNXP $33.71
- Resistance Level
- PAMT N/A
- TNXP $38.13
- Average True Range (ATR)
- PAMT 0.00
- TNXP 2.62
- MACD
- PAMT 0.00
- TNXP -0.44
- Stochastic Oscillator
- PAMT 0.00
- TNXP 61.01
About PAMT PAMT CORP Common Stock
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.